Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Endonovo Therapeutics (ENDV) Change in Receivables (2018 - 2023)

Endonovo Therapeutics has reported Change in Receivables over the past 7 years, most recently at $3120.0 for Q1 2023.

  • Quarterly results put Change in Receivables at $3120.0 for Q1 2023, changed N/A from a year ago — trailing twelve months through Mar 2023 was -$3413.0 (changed N/A YoY), and the annual figure for FY2021 was $2.0, up 100.01%.
  • Change in Receivables for Q1 2023 was $3120.0 at Endonovo Therapeutics, up from -$6148.0 in the prior quarter.
  • Over the last five years, Change in Receivables for ENDV hit a ceiling of $11466.0 in Q4 2019 and a floor of -$19660.0 in Q1 2020.
  • Median Change in Receivables over the past 4 years was $970.5 (2020), compared with a mean of $59.92.
  • Biggest five-year swings in Change in Receivables: skyrocketed 1549.78% in 2019 and later tumbled 232600.0% in 2021.
  • Endonovo Therapeutics' Change in Receivables stood at $11466.0 in 2019, then plummeted by 99.99% to $1.0 in 2020, then crashed by 614900.0% to -$6148.0 in 2021, then soared by 150.75% to $3120.0 in 2023.
  • The last three reported values for Change in Receivables were $3120.0 (Q1 2023), -$6148.0 (Q4 2021), and -$2325.0 (Q3 2021) per Business Quant data.